1. What data in particular will be shared?
   Response - Individual participant data that underlie the results reported in this article, after de-identification (text, tables, figures, and appendices).
   


2. What additional supporting information will be shared?
   Response -  Statistical Analysis Plan
   Response - Clinical Study Report
   
   
3. Who will be able to view these files?
   Response - Researchers whose proposed use of the data has been approved by an independent review committee identified for this purpose.
   


4. For what types of analyses will this data be available?
   Response - To achieve aims in the approved proposal.
   


5. By what mechanism will data be made available?
   Response - Proposals should be directed to [nivsha1985@gmail.com].
   


6. For how long will this data be available start date provided 01-06-2027 and end date provided 01-06-2029?
   Response - Beginning 9 months and ending 36 months following article publication.
   


7. Any URL or additional information regarding plan/policy for sharing IPD? 
   Additional Information - NIL

 In breast cancer patients, the optimal surgical management of the axilla has been controversial especially in node positive patients. Until recently, axillary lymph node dissection (ALND) was considered standard in such patients. ALND not only provided accurate staging by assessing pathological lymph node status but also ensured locoregional control as well as helped guiding systemic therapy. Nevertheless, it is associated with higher morbidity in terms of lymphedema, shoulder syndrome, recurrent seromas, sensory loss in arm etc. This gradually led to identification of sentinel lymph node biopsy (SLNB) as a feasible alternative with much lesser morbidity. Though SLNB is now considered standard of care in node negative early breast cancer, its role in initially node positive patients who achieve complete clinical axillary response with neoadjuvant chemotherapy (NACT) is still evolving. Initial trials on SLNB in node positive breast cancer patients receiving NACT had high FNR of 13-15%. Attempts to decrease the FNR further, led to evolution of Targeted Axillary Dissection (TAD) which involves marking of suspected lymph node prechemotherapy and then localizing and removing that node along with other sentinel lymph nodes. Various methods of marking and localising the suspected nodes have been reported in literature, but there is lack of consensus on the most appropriate or feasible technique.  While few techniques like radioactive seed localisation has good identification rate, difficulty in procurement, strict regulatory guidelines of use and high cost on radioactive isotopes has prevented its widespread adoption. Also, there is lack of data on targeted axillary dissection from Indian subcontinent.